Passage Bio Statistics

Total Valuation

Passage Bio has a market cap or net worth of $38.11 million. The enterprise value is -$20.90 million.

Market Cap	38.11M
Enterprise Value	-20.90M

Important Dates

The next estimated earnings date is Monday, March 3, 2025, before market open.

Earnings Date	Mar 3, 2025
Ex-Dividend Date	n/a

Share Statistics

Passage Bio has 61.77 million shares outstanding. The number of shares has increased by 7.30% in one year.

Current Share Class	61.77M
Shares Outstanding	61.77M
Shares Change (YoY)	+7.30%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	0.50%
Owned by Institutions (%)	38.86%
Float	48.26M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.52
P/TBV Ratio	0.52
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.15, with a Debt / Equity ratio of 0.36.

Current Ratio	5.15
Quick Ratio	5.00
Debt / Equity	0.36
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -69.15% and return on invested capital (ROIC) is -34.49%.

Return on Equity (ROE)	-69.15%
Return on Assets (ROA)	-30.85%
Return on Capital (ROIC)	-34.49%
Revenue Per Employee	n/a
Profits Per Employee	-$1.19M
Employee Count	58
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -31.36% in the last 52 weeks. The beta is 1.54, so Passage Bio's price volatility has been higher than the market average.

Beta (5Y)	1.54
52-Week Price Change	-31.36%
50-Day Moving Average	0.68
200-Day Moving Average	0.87
Relative Strength Index (RSI)	45.37
Average Volume (20 Days)	881,555

Short Selling Information

The latest short interest is 3.85 million, so 6.24% of the outstanding shares have been sold short.

Short Interest	3.85M
Short Previous Month	1.70M
Short % of Shares Out	6.24%
Short % of Float	7.99%
Short Ratio (days to cover)	6.61

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-69.34M
Pretax Income	-76.57M
Net Income	-68.80M
EBITDA	-66.17M
EBIT	-69.34M
Earnings Per Share (EPS)	-$1.17

Full Income Statement

Balance Sheet

The company has $84.83 million in cash and $25.82 million in debt, giving a net cash position of $59.01 million or $0.96 per share.

Cash & Cash Equivalents	84.83M
Total Debt	25.82M
Net Cash	59.01M
Net Cash Per Share	$0.96
Equity (Book Value)	72.72M
Book Value Per Share	1.18
Working Capital	70.27M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$59.03 million and capital expenditures -$33,000, giving a free cash flow of -$59.06 million.

Operating Cash Flow	-59.03M
Capital Expenditures	-33,000
Free Cash Flow	-59.06M
FCF Per Share	-$0.96

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Passage Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.30%
Shareholder Yield	-7.30%
Earnings Yield	-180.53%
FCF Yield	-154.97%

Analyst Forecast

The average price target for Passage Bio is $8.00, which is 1,196.60% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$8.00
Price Target Difference	1,196.60%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1